Prognostic Factors Effective on Survival in Unifocal Borderline Luminal B HER2-Negative and Triple-Negative Breast Cancers: a Cross-Sectional Study-Reference-Cited by-同舟云学术

Prognostic Factors Effective on Survival in Unifocal Borderline Luminal B HER2-Negative and Triple-Negative Breast Cancers: a Cross-Sectional Study

Published:2022-01-24 Issue:6 Volume:84 Page:1231-1238
ISSN:0972-2068
Container-title:Indian Journal of Surgery
language:en
Short-container-title:Indian J Surg

Author:

Dal Fatih^ORCID,Ökmen Hasan^ORCID,Ulusan Kıvılcım^ORCID,Havare Semiha Battal^ORCID,Trabulus Fadime Didem Can^ORCID,Çolak Şükrü^ORCID,Ferlengez Ekrem^ORCID,Sari Serkan^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

https://link.springer.com/content/pdf/10.1007/s12262-022-03294-7.pdf

Reference28 articles.

1. Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2(10):1102–1109. https://doi.org/10.1200/JCO.1984.2.10.1102

2. Mosly D, Turnbull A, Sims A et al (2018) Predictive markers of endocrine response in breast cancer. World J Exp Med 8(1):1–7. https://doi.org/10.5493/wjem.v8.i1.1

3. Ogawa Y, Moriya T, Kato Y et al (2004) Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 11(3):267–275. https://doi.org/10.1007/bf02984548

4. Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer(unabridged version). Arch Pathol Lab Med 134(7):e48-72. https://doi.org/10.1043/1543-2165-134.7.e48

5. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304